Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by JamesNeven1983on Jun 25, 2020 10:40pm
105 Views
Post# 31193489

RE:RE:Jack and Belgium

RE:RE:Jack and Belgium .025 average here .. .015 coming? Sure I'll be adding more to brother.
Jack4000 wrote:
scaley wrote: You folks around? Id like to hear your opinion
Wont like part of my opinion. Were going down to a penny and a half as soon as the PP is announced and will stay thereabouts till it closes. No force on earth or good announcement will change that fact so, weak hands can still play Nervous Nancy till its over. After that though, things will get pretty active. look forward to the merger going forward in July and Salzman taking over along with the RS which will boost SP to 5 or six cents (pre split), BARDA contracts and a SP rise up to 10 - 12 cents (pre split) as institutional investors jump on board. With the increased activity and liquidity due to the stock trading at between two and three dollars youll find that the progress reports Which to date have had a meh effect will have a much more positive influence on the stock. Dont lose sight that two of our programs will probably be paid for by BARDA both with guaranteed markets. COVID vaccines are only being effective on 70% of the population at best, not being produced in annual quantities to apply worldwide for years, our treatment will still have value for a decade at least. The CILI is an ongoing asset which has an end application of filling up the US, UN, WHO and many other nations national stock piles not to mention international military installations in case of terrorist attack. These treatments have to be on the ground and ready near the location the attack occcurs thus, were looking at billions of them, not hundreds of thousands but billions. Our GVHD program is still valuable and only lacked funding. At any point that funding can be garnered from the serious uptick in SP with loans or debentures. In the fall lol for the Stero Deal to be revisited as the company solidified its base. I can go on but you can see that when I read negative stuff I just chuckle and add.


<< Previous
Bullboard Posts
Next >>